Ìṣègùn
Ìṣe ìṣègùn jẹ́ iṣẹ́ ọnà, kì í ṣe òwò; ó jẹ́ ìpè, kì í ṣe òwò.
— (1903)
Ọ̀dọ́ aláìsàn mẹ́ta wà láàyè láìsí àrùn fún ọ̀pọ̀ ọdún lẹ́yìn experimental T cell. Phase 1 trial kò lè fi hàn ohun tó fa outcome wọ̀nyẹn
ReMIND infused laboratory-grown T cell tí a ṣe láti ẹ̀jẹ̀ patient kọ̀ọ̀kan fúnra rẹ̀ sínú ọmọ àti young adult 33 pẹ̀lú high-risk brain tumor. Wọ́n expand cell láti react sí protein mẹ́ta tí ó lè wà nínú cancer cell. Patient mẹ́ta ní disease-free interval ju 31.8, 41.2 àti 51.6 months láti first infusion, pẹ̀lú complete response kan lábẹ́ scan criterion. Nínú aggressive brainstem-tumor group, kò sí scan tí shrinkage tàbí disappearance rẹ̀ tó dé predefined response threshold trial. Early safety-and-dose trial kan náà record death kan tó serious tó láti count lòdì sí dose increase lábẹ́ rule rẹ̀. Láìsí comparison group, study kò lè show bóyá T cell caused outcome mẹ́ta náà.
KRAS vaccine dá T cell response sílẹ̀ nínú 18 lára 20 high-risk participant — kì í ṣe proof pé ó dènà pancreatic cancer
Single-centre phase I trial kan test six-mutation KRAS peptide vaccine nínú ènìyàn 20 pẹ̀lú inherited tàbí familial pancreatic-cancer risk àti pancreatic cystic abnormality. Vaccine-related adverse event jẹ́ grade 1 tàbí 2, participant 18 pade prespecified blood T cell response criterion, small-subset analysis sì rí immune persistence kan títí dé ọdún méjì. Kò sí participant tó develop pancreatic cancer ní median 16.5 months, ṣùgbọ́n study jẹ́ open-label, non-randomized, single-arm, a kò sì design rẹ̀ láti test prevention. Vaccine náà experimental; result wọ̀nyí justify larger efficacy trial dípò claim pé cancer ti jẹ́ prevented.
Macaque HIV model kan mú rare broad antibodies appear kíákíá — vaccine clue, kì í tíì ṣe vaccine
Science study kan engineer SHIV model tí expose HIV V3-glycan epitope ní steps méjì: àkọ́kọ́ nípa provoking antibodies sí altered V1 loop, lẹ́yìn náà nípa selecting escape variants tí open target fún broadly neutralizing antibody precursors. Nínú macaques, engineered virus elicited potent V3-glycan broadly neutralizing antibodies nínú 14 of 22 animals within a year, compared pẹ̀lú none of 14 given parental virus. Result jẹ́ useful blueprint fún immunogen design, kì í ṣe proof pé HIV vaccine works nínú humans.
Clinical AI kan tó dà bí safe, tó sì improve paperwork — ṣùgbọ́n kò improve patient outcomes
Pragmatic cluster-randomized trial nínú 16 Kenyan primary care facilities test generative-AI decision-support tool tí a fi kún record clinical officers. Nínú 9,691 patients, strict 14-day expert-adjudicated composite of treatment failure jẹ́ 2.2% pẹ̀lú tool versus 2.0% láìsí rẹ̀ (adjusted odds ratio 0.77, 95% CI 0.55-1.08, P = 0.13) — no significant difference. Tool kò fi safety signal hàn, ó improve documentation kọjá all rated domains, prescribing àti satisfaction unchanged, antibiotic costs sì trend lower. Èyí kì í ṣe failed study; ó jẹ́ rare, honest one — measured on patients, not benchmarks — tó fi hàn pé tool tí looked safe, tó help process, kò demonstrably help patients nínú two weeks, benefit kankan sì yóò nilo much larger trial láti detect.
Oral norovirus vaccine kan reduce infection nínú challenge trial — ṣùgbọ́n ó miss clinical endpoint rẹ̀
Phase 2b human-challenge study test oral tablet vaccine against GI.1 norovirus. Vaccinated adults less likely láti ní qPCR-detectable infection after challenge, show mucosal immune responses, shed less viral RNA ní some time points. Ṣùgbọ́n prespecified clinical gastroenteritis endpoint kò met, trial lo controlled high-dose challenge nínú healthy adults, kò sì measure real-world transmission tàbí protection against currently dominant GII.4 genotypes. Èyí jẹ́ promising step toward norovirus vaccine, kì í ṣe proof pé one has arrived.
Nínú eku, ìtọ́jú growth factor ìgbésẹ̀ méjì tún àwọn egungun digit tí a gé kúrò hù — láìpéye
Níbi tí gígé digit eku ti sábà máa ń sàn pẹ̀lú àpá, fífi FGF2 àti lẹ́yìn náà BMP2 sí i dá blastema sílẹ̀, ó sì tún phalanx tó sọnù àti isẹ́pọ̀ kékeré hù — wọ́n jọ ti àkọ́kọ́ ṣùgbọ́n wọn kò bá wọn mu, wọ́n sì jìnnà sí gbogbo ẹsẹ̀-ọwọ́. Ó dábàá pé sẹ́ẹ̀lì àti àmì ìtún-hù lè wà níbi tí ẹranko ọmú ti sábà kùnà: proof of principle nínú eku, kì í ṣe ìtọ́jú ènìyàn.